FIELD: biochemistry.
SUBSTANCE: invention relates to use of Axl as biomarker for detecting occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, where upregulation of Axl expression is indicative of occurrence of (EMT). Invention also relates to a methods for detecting occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Axl expression, to identification of substances capable of inhibiting or reversing EMT, to a method for prediction of susceptibility of a subject to treatment with an Axl inhibitor.
EFFECT: invention enables to use determination of expression of Axl as useful marker for detecting occurrence of EMT, which can be used for diagnosis, prediction and therapy of cancer.
18 cl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| USE OF microRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSTICS AND TREATMENT | 2014 |
|
RU2644247C2 |
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
| MONOCLONAL ANTIBODIES CAPABLE OF BINDING WITH AXL PROTEIN AND THEIR APPLICATION | 2008 |
|
RU2559530C2 |
| METHOD OF IN VITRO DETERMINATION OF PROGNOSIS OF DISEASE DEVELOPMENT IN PATIENT WITH CANCER AND METHOD OF IN VITRO MONITORING EFFECT OF THERAPY ADMINISTERED TO PATIENT WITH CANCER | 2006 |
|
RU2434946C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | 2014 |
|
RU2679500C2 |
| ANTI-AXL ANTIBODIES AND COMPOSITIONS | 2021 |
|
RU2837590C1 |
